GSP Crop Science IPO GMP, Review, Price Band & All Key Details (2026)

India's agrochemical sector is getting a new publicly listed player. GSP Crop Science Limited, a 40-year-old Ahmedabad-based manufacturer of crop protection products, opened its ₹400 crore IPO for public subscription on March 16, 2026. If you are evaluating whether to apply, this article breaks down everything — from the company's financials and business model to the GSP Crop Science IPO GMP and valuation — so you can make an informed decision.

What Is GSP Crop Science?

Founded in 1985, GSP Crop Science Limited is a research-driven agrochemical company headquartered in Ahmedabad, Gujarat. The company manufactures and distributes a wide range of crop protection products, including:

• Insecticides — to protect crops from insect damage
• Herbicides (Weedicides) — for effective weed control, reducing reliance on manual weeding
• Fungicides — to prevent and treat fungal infections and crop diseases
• Plant Growth Regulators (PGRs) — chemicals that regulate plant development, flowering, root growth, and fruiting to improve yield and quality

The company operates across two primary business segments:

1. Technicals — concentrated active ingredient manufacturing (15,120 MTPA capacity)
2. Formulations — finished crop protection products combining active ingredients with additives (43,672 MTPA capacity)
3. Intermediates — with an additional 5,400 MTPA capacity

This integrated model, spanning the full agrochemical value chain, gives GSP Crop Science significant cost and supply chain advantages over pure-play formulators.

Company Footprint and Scale

GSP Crop Science has built a substantial operating presence over four decades:

The company exports to markets in Latin America (Brazil, Uruguay), North America (United States), Asia-Pacific (Vietnam, Singapore, Australia), and the Middle East (UAE). This geographic diversification provides a meaningful hedge against domestic demand volatility tied to monsoon cycles.

GSP Crop Science IPO: Key Details at a Glance

IPO Structure: Fresh Issue vs. OFS

Of the total ₹400 crore issue:

• Fresh Issue (₹240 crore): New shares are issued by the company. The proceeds come to GSP Crop Science and will be used for business purposes.
• OFS (₹160 crore): Existing promoter shareholders are selling their shares. This money goes to the selling shareholders, not the company.

This structure is important for investors to understand. The fresh issue portion directly benefits the company, while the OFS simply allows promoters to exit or reduce their stake.

Quota Breakdown for Public Subscription

Anchor Investor Allotment

Ahead of the public issue, GSP Crop Science raised ₹120 crore from anchor investors on March 13, 2026, with 37.5 lakh shares allotted at ₹320 per share. Anchor investor participation signals institutional confidence in the offering and is generally seen as a positive indicator for IPO demand.

Use of IPO Proceeds

The ₹240 crore raised through the fresh issue will be deployed as follows:

• ₹170 crore: Repayment or pre-payment of outstanding borrowings
• Remaining amount: General corporate purposes

This is a debt-reduction IPO. As of December 2025, GSP Crop Science's total outstanding borrowings stood at approximately ₹478.8 crore. The ₹170 crore repayment will reduce the debt burden materially, improving the interest coverage ratio and freeing up cash flows for operations and growth.

Financial Performance: Revenue, Profit, and Growth

GSP Crop Science has delivered a strong improvement in profitability over the past three years, which is the most important thing to understand before applying to this IPO.

Key observations from the financials:

1. Profit has grown ~365% from FY23 to FY25 — from ₹17.5 crore to ₹81.4 crore — even as revenues grew more modestly. This indicates significant operating leverage and margin expansion.
2. H1 FY26 PAT already equals full-year FY25 PAT — the company earned ₹81 crore in just the first six months of FY26 (April to September 2025), suggesting the full-year FY26 profit could be significantly higher than FY25.
3. Revenue declined in FY24 — Revenue fell from ₹1,203 crore in FY23 to ₹1,152 crore in FY24. This was partly due to the global agrochemical downcycle driven by price pressure on technicals. The subsequent recovery in FY25 and H1 FY26 indicates stabilization and demand recovery.

Source: GSP Crop Science DRHP filed with SEBI and Red Herring Prospectus (RHP).

Valuation: Is the GSP Crop Science IPO Fairly Priced?

At the upper price band of ₹320, GSP Crop Science is priced at approximately 9.6x its FY25 earnings per share — making it one of the more attractively valued IPOs in the agrochemical space.

If annualized H1 FY26 earnings are used as the forward estimate, the valuation appears even cheaper. The significant discount to peers has been a key talking point in analyst reviews, with several brokerages noting it as a potential "discounted entry" opportunity into the agrochemical sector.

Source: NSE/BSE filings and publicly available analyst reports. P/E multiples are approximate and based on trailing twelve months earnings.

GSP Crop Science IPO GMP (Grey Market Premium)

The GSP Crop Science IPO GMP today is ₹0, indicating that the grey market is pricing the stock at or near the issue price of ₹320.

What Is GMP and Why Does It Matter?

The Grey Market Premium (GMP) is an unofficial, unregulated market where IPO shares are bought and sold before their official listing on the stock exchange. The GMP gives a real-time pulse of investor sentiment and the anticipated listing price premium.

• Positive GMP: Grey market expects the stock to list above the issue price.
• Zero/Flat GMP: Grey market expects listing around the issue price.
• Negative GMP: Grey market is pricing in a potential listing discount.

GSP Crop Science IPO GMP Analysis

The current GMP of ₹0 for the GSP Crop Science IPO means:

• Expected listing price: ~₹320 (the upper end of the price band)
• The grey market is not pricing in any listing pop
• This does NOT necessarily mean the stock is a poor investment — it may simply reflect broader market caution or the subdued primary market sentiment in March 2026

A flat GMP with a low PE multiple can actually be a constructive setup for long-term investors. The market may be underestimating the earnings power of H1 FY26 if annualized.

GMP data sourced from grey market tracking platforms (Investorgain, IPO Watch). Important disclaimer: GMP is an unofficial, unregulated indicator and should NOT be the basis for your investment decision. It is purely speculative and can change rapidly.

Promoter and Shareholding Structure

GSP Crop Science's promoters hold a 98.25% pre-IPO stake, which will dilute post-listing.

Promoters include:

• Bhavesh Vrajmohan Shah (Managing Director)
• Tirth Kenal Shah
• Vilasben Vrajmohan Shah
• Falguni Kenal Shah
• Alpha Trust
• Kappa Trust

The high promoter holding pre-IPO indicates a closely-held, family-run business taking the public market route for the first time. Post-IPO, promoter stakes will decline as new shares are issued and the OFS shares change hands, but promoters are expected to retain a majority stake.

Competitive Landscape

GSP Crop Science operates in India's ₹60,000+ crore agrochemical industry, which is among the most competitive globally. Key listed competitors include:

• PI Industries — a premium R&D-driven player, primarily in exports
• Dhanuka Agritech — strong domestic distribution network
• India Pesticides — technicals-focused, similar business model
• Heranba Industries — formulations and technicals
• Excel Industries — diversified chemicals and agrochemicals
• Safex Chemicals — unlisted competitor

GSP Crop Science's integrated model (technicals + formulations), 40-year brand equity, and export presence across 37 countries are its primary competitive moats.

Risks to Consider Before Investing

1. High debt levels: Even after deploying ₹170 crore to reduce borrowings, the company will still carry significant debt. As of December 2025, borrowings were ~₹478.8 crore.
2. Agrochemical downcycle risk: The industry went through a pricing downcycle in FY24 when global technical prices crashed. A repeat of this scenario could compress margins.
3. Dependence on monsoon and weather: Agrochemical demand in India is heavily linked to the monsoon. A poor monsoon year will hurt domestic volumes.
4. Regulatory and environmental compliance: The agrochemical industry faces stringent CPCB and state pollution board norms. Any regulatory action on products or manufacturing facilities could impact operations.
5. Input price volatility: Raw material costs for agrochemical manufacturing can be volatile, especially for imported intermediates tied to Chinese chemical exports.
6. Concentrated shareholding pre-IPO: With promoters holding 98.25% before the IPO, the public float will be limited. This can lead to higher stock volatility post-listing.

GSP Crop Science IPO: Key Dates Summary

DRHP Filed with SEBI

GSP Crop Science filed its Draft Red Herring Prospectus (DRHP) with SEBI in December 2024. The DRHP is publicly available on the BSE India website and the SEBI website, and contains detailed disclosures about the company's business, financials, risk factors, and IPO structure.

Investors who want to go beyond this article are strongly encouraged to read the DRHP before investing, particularly the risk factors section (which is often the most important part of any prospectus).

Should You Apply to the GSP Crop Science IPO?

Here is a balanced summary of the bull and bear case:

Bull case:

• Deep P/E discount to peers (~9.6x vs. 15–37x for listed agrochemical companies)
• Strong profit growth: PAT grew from ₹17.5 crore in FY23 to ₹81.4 crore in FY25
• H1 FY26 profits already match full FY25 — forward earnings look strong
• Integrated technicals + formulations model with 40+ years of track record
• ₹120 crore anchor investor participation provides credibility
• Export presence in 37 countries, 524 product registrations, and 102 patents

Bear case:

• GMP is flat at ₹0 — no immediate listing gain expected
• High debt (₹478.8 crore), though IPO proceeds partially address this
• Agrochemical sector exposed to monsoon risk, input price swings, and regulatory changes
• Revenue was flat to declining in FY24, showing vulnerability to sector cycles
• Subdued primary market sentiment in March 2026

The IPO is best suited for investors with a medium-to-long-term horizon who believe in the structural growth story of Indian agrochemicals and are comfortable with the sector's inherent risks.

Conclusion

The GSP Crop Science IPO offers exposure to one of India's oldest and most integrated agrochemical manufacturers at a compelling valuation. The company's four decades of operational history, strong profit recovery, and diversified product portfolio make it an interesting investment proposition. The low P/E multiple — a significant discount to peers — along with a rapidly improving earnings trajectory are the strongest arguments in its favour.

The current GSP Crop Science IPO GMP of ₹0 suggests the market is not pricing in a listing pop, which means short-term traders may not find this IPO exciting. But for investors focused on fundamentals and long-term value creation in the agriculture and agrochemical space, this is a name worth examining closely.

As always, read the DRHP, assess your risk appetite, and consult your financial advisor before making any investment decision.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investing in IPOs involves market risk. Please read all offer documents carefully before investing.